CPRX - カタリスト・ファ―マシュ―ティカルズ （Catalyst Pharmaceuticals Inc.）

In last trading session, Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) saw 1.93 million shares changing hands with its beta currently measuring 1.45. Company’s recent per share price level of $13.98 trading at $0.44 or 3.25% at ring of the bell on the day assigns it a market valuation of $1.47B. That closing price of CPRX’s stock is … Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Jump 3.25%, More Rally Possible Read More »

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) marked $14.12 per share on Monday, up from a previous closing price of $14.02. While Catalyst Pharmaceuticals Inc. has overperformed by 0.71%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CPRX rose by 158.14%, with highs and lows ranging from $15.07 to […]

The shares of Catalyst Pharmaceuticals (CPRX) dropped ~8% in the morning hours Wednesday to record the biggest intraday loss in over three months after Roth Capital Partners downgraded…

The share price of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) rose to $14.91 per share on Tuesday from $14.31. While Catalyst Pharmaceuticals Inc. has overperformed by 4.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CPRX rose by 161.58%, with highs and lows ranging from $14.80 to $4.81, […]

Today, we check back in on fast-growing biopharma Catalyst Pharmaceuticals for the first time since last October.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)s stock price traded up 2.4% during mid-day trading on Friday . The company traded as high as $6.90 and last traded at $6.88. 2,192 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,217,669 shares. The stock had previously closed at $6.72. Separately, HC [] The post Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 2.4% Higher appeared first on ETF Daily News .

Fisher Asset Management LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 201,801 shares of the biopharmaceutical companys stock, valued at approximately $1,070,000. Fisher Asset Management LLC owned 0.20% of []

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Gary Ingenito sold 3,612 shares of the firms stock in a transaction on Tuesday, December 7th. The shares were sold at an average price of $6.99, for a total transaction of $25,247.88. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Shares []

CORAL GABLES, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that its collaboration partner DyDo Pharma ("DyDo") has initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of Catalyst''s FIRDAPSE ® (amifampridine) 10 mg tablets for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS").

Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY ) total return over the last 12 months is 29.5%. But there is no question some big-name stocks performed better than others along the way. Catalysts Bumpy Ride: One company that has been a great investment in the last year has been the biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ). Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in recent years came in 2018 when the companys Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan in 2019. In early 2020, Catalyst aggressively expanded its sales team to help monetize Firdapse and the company is actively undergoing trials to potentially expand Firdapses label to muscle-specific kinase myasthenia gravis (MuSK-MG) and other indications.

Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY ) total return over the last 12 months is 29.5%. But there is no question some big-name stocks performed better than others along the way. Catalysts Bumpy Ride: One company that has been a great investment in the last year has been the biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ). Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in recent years came in 2018 when the companys Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan in 2019. In early 2020, Catalyst aggressively expanded its sales team to help monetize Firdapse and the company is actively undergoing trials to potentially expand Firdapses label to muscle-specific kinase myasthenia gravis (MuSK-MG) and other indications.

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 1.10% to the previous days close as strong demand from buyers drove the stock to $7.38. Actively observing the price movement in the last trading, the stock closed the session at $7.30, falling within a range of $7.18 The Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Metrics You Need To Know Right Now Read More »

Brokerages expect that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will report earnings of $0.11 per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with estimates ranging from $0.10 to $0.11. Catalyst Pharmaceuticals also posted earnings of $0.11 per share in the same quarter last year. The firm […]

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX)s traded shares stood at 0.59 million during the last session, with the companys beta value hitting 1.33. At the close of trading, the stocks price was $7.32, to imply an increase of 0.27% or $0.02 in intraday trading. The CPRX shares 52-week high remains $7.58, putting it -3.55% down since that What Could Change After Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Gains 56.01% From The High-Point? Read More »

Wall Street analysts expect that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will announce earnings per share (EPS) of $0.11 for the current quarter, according to Zacks. Four analysts have issued estimates for Catalyst Pharmaceuticals earnings. The highest EPS estimate is $0.11 and the lowest is $0.10. Catalyst Pharmaceuticals also posted earnings of $0.11 per share during the []